{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:28:05Z","timestamp":1790803685644,"version":"4.1.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011022","name":"Vertex Pharmaceuticals Incorporated","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011022","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.jcf.2025.11.014","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T04:23:53Z","timestamp":1764908633000},"page":"284-289","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Improvements in health-related quality of life in people with cystic fibrosis \u22656 years of age treated with vanzacaftor\/tezacaftor\/deutivacaftor"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8389-3809","authenticated-orcid":false,"given":"Claire E.","family":"Wainwright","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2856-752X","authenticated-orcid":false,"given":"Teja","family":"Thorat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Conner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1785-3870","authenticated-orcid":false,"given":"Bradley S.","family":"Quon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Duckers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4098-780X","authenticated-orcid":false,"given":"Yiyue","family":"Lou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1299-2302","authenticated-orcid":false,"given":"Chen","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqing","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-8106-4250","authenticated-orcid":false,"given":"Ling","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"McGarry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcf.2025.11.014_bib0001","first-page":"7","article-title":"Disease-modifying drug therapy in cystic fibrosis","volume":"26","author":"Harman","year":"2018","journal-title":"Paediatr Respir Rev"},{"key":"10.1016\/j.jcf.2025.11.014_bib0002","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1016\/S0140-6736(16)00576-6","article-title":"Cystic fibrosis","volume":"388","author":"Elborn","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jcf.2025.11.014_bib0003","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1159\/000095375","article-title":"Causes of variation in the Cystic fibrosis phenotype","volume":"64","author":"Cutting","year":"2006","journal-title":"Annales Nestle (English ed.)"},{"key":"10.1016\/j.jcf.2025.11.014_bib0004","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1016\/S0140-6736(09)60327-5","article-title":"Cystic fibrosis","volume":"373","author":"O'Sullivan","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.jcf.2025.11.014_bib0005","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.jcf.2008.05.010","article-title":"Quality of life in patients with Cystic Fibrosis: association with anxiety and depression","volume":"7","author":"Havermans","year":"2008","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2025.11.014_bib0006","doi-asserted-by":"crossref","first-page":"585","DOI":"10.2147\/PPA.S159306","article-title":"Living with cystic fibrosis - a qualitative study of a life coaching intervention","volume":"12","author":"Knudsen","year":"2018","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.jcf.2025.11.014_bib0007","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1002\/ppul.24157","article-title":"Rapid therapeutic advances in CFTR modulator science","volume":"53","author":"Clancy","year":"2018","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2025.11.014_bib0008","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41572-024-00538-6","volume":"10","author":"Mall","year":"2024","journal-title":"Cyst fibros Nat Rev Dis Primers"},{"key":"10.1016\/j.jcf.2025.11.014_bib0009","unstructured":"US Cystic Fibrosis Foundation. 2023 Patient registry annual report. 2024."},{"key":"10.1016\/j.jcf.2025.11.014_bib0010","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jcf.2023.02.004","article-title":"Elexacaftor\/tezacaftor\/ivacaftor projected survival and long-term health outcomes in people with cystic fibrosis homozygous for F508del","volume":"22","author":"Lopez","year":"2023","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2025.11.014_bib0011","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/S2213-2600(24)00411-9","article-title":"Vanzacaftor-tezacaftor-deutivacaftor versus elexacaftor-tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials","volume":"13","author":"Keating","year":"2025","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jcf.2025.11.014_bib0012","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/S2213-2600(24)00407-7","article-title":"Vanzacaftor-tezacaftor-deutivacaftor for children aged 6-11 years with cystic fibrosis (RIDGELINE Trial VX21-121-105): an analysis from a single-arm, phase 3 trial","volume":"13","author":"Hoppe","year":"2025","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jcf.2025.11.014_bib0013","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jcf.2022.08.018","article-title":"Non-respiratory health-related quality of life in people with cystic fibrosis receiving elexacaftor\/tezacaftor\/ivacaftor","volume":"22","author":"Fajac","year":"2023","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2025.11.014_bib0014","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s41687-025-00879-0","article-title":"Improved quality of life in cystic fibrosis patients observed up to 36 months after starting Elexacaftor\/Tezacaftor\/Ivacaftor treatment","volume":"9","author":"Francesca","year":"2025","journal-title":"J Patient Rep Outcomes"},{"key":"10.1016\/j.jcf.2025.11.014_bib0015","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s41687-024-00697-w","article-title":"Psychometric performance of the CFQ-R-8D compared to the EQ-5D-3L and SF-6D in people with cystic fibrosis","volume":"8","author":"Mukuria","year":"2024","journal-title":"J Patient-Rep Outcomes J Patient Rep Outcomes"},{"key":"10.1016\/j.jcf.2025.11.014_bib0016","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.jval.2022.12.002","article-title":"Development of the Cystic Fibrosis questionnaire-revised-8 dimensions: estimating utilities from the Cystic fibrosis questionnaire-revised","volume":"26","author":"Sarah","year":"2023","journal-title":"Value Health"},{"key":"10.1016\/j.jcf.2025.11.014_bib0017","article-title":"Exploring the complexity of cystic fibrosis (CF) and psychosocial wellbeing in the 2020s: current and future challenges","author":"Dobra","year":"2024","journal-title":"Paediatr Respir Rev"},{"key":"10.1016\/j.jcf.2025.11.014_bib0018","doi-asserted-by":"crossref","first-page":"S172","DOI":"10.1016\/S1569-1993(19)30698-8","article-title":"P406 Behavioural problems in children with cystic fibrosis - are we really looking for them?","volume":"18","author":"Maitra","year":"2019","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2025.11.014_bib0019","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s40474-021-00235-z","article-title":"Health-related quality of life in children with developmental disorders","volume":"8","author":"Schoemaker","year":"2021","journal-title":"Curr Dev Disord Rep"},{"key":"10.1016\/j.jcf.2025.11.014_bib0020","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1167\/tvst.7.4.15","article-title":"Parent-child agreement on health-related quality of life in Congenital Glaucoma","volume":"7","author":"Gothwal","year":"2018","journal-title":"Transl Vis Sci Technol"},{"key":"10.1016\/j.jcf.2025.11.014_bib0021","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s13023-021-01748-x","article-title":"Parent-child-agreement on health-related quality of life and its determinants in patients born with Esophageal Atresia: a Swedish-German cross-sectional study","volume":"16","author":"Witt","year":"2021","journal-title":"Orphanet J Rare Dis"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199325025275?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199325025275?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T11:38:13Z","timestamp":1781782693000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199325025275"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S1569199325025275"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2025.11.014","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Improvements in health-related quality of life in people with cystic fibrosis \u22656 years of age treated with vanzacaftor\/tezacaftor\/deutivacaftor","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2025.11.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2025 Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.","name":"copyright","label":"Copyright"}]}}